AIMS Cancer Outcomes Study (ACOS)

Recruiting now – AIMS CANCER OUTCOMES STUDY

AIMS Cancer Outcomes Study (ACOS)
We want to know if receiving naturopathic and integrative oncology care, in addition to surgery, chemotherapy, and radiation, will help people with cancer to live longer, healthier lives. We want to determine how well our patients, who receive treatment at AIMS Institute, do over time. You will not directly benefit from the study. However, you may benefit from the medical care you receive and information gathered during the course of this study may help us begin to assess the longer-term effects of integrative oncology outpatient care on health in cancer patients.

To learn more, read the full informed consent below. All AIMS patients receiving integrative oncology care will be asked to participate in this study. If you have more questions regarding the informed consent or about ACOS, you can discuss it with your AIMS provider at the time of your visit. Clinical Trials.gov NCT04495790.

INFORMED CONSENTS

ACOS Adult Informed Consent

ACOS Parental-Guardian Permission Form

ACOS Minor Assent Form

Latest Blog Posts

A Holistic Solution to Health Disparities: Naturopathic Medicine and Culturally Competent Care

Healthcare Disparities in African American Communities African Americans continue to face significant disparities in healthcare. From higher mortality rates for chronic conditions like cancer and heart disease to underdiagnosis of autoimmune disorders, these inequities stem from systemic racism, implicit bias, and a lack of cultural sensitivity among providers. Studies show that Black patients are less likely to receive adequate pain management and more likely to feel unheard or dismissed during medical visits. These disparities erode trust in the healthcare system and lead to poorer outcomes and avoidable suffering. For many, navigating the system can feel isolating and disempowering, leaving them ...

At AIMS Institute we prescribe low dose oral naltrexone for ‘long COVID’

A recent paper in the Frontiers in Medicine states that An underutilized intervention for long COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue ...

Unusual Suspects

Psychedelic Therapies Gain New Advocates Texas Law Magazine Written by Robin Berghaus. Art by Matthieu Bourel Published November 6, 2024 Marcus Capone served seven combat tours as a Navy SEAL — including missions with SEAL Team Six, the nation’s preeminent counterterrorism unit — before being medically retired in 2013. For years, he struggled to find effective treatments for his traumatic brain injuries, depression, and post-traumatic stress disorder. Capone tried antidepressants, talk therapy, hyperbaric oxygen therapy, transcranial magnetic stimulation, and he visited several brain clinics. Nothing worked. When Capone’s life began falling apart, he considered suicide. His wife was just as ...